Icure acquires approval of Phase 3 clinical trial of donepezil patches for the first time
Icure, a pharmaceutical R&D company owning the original technology of the Transdermal Drug Delivery System(TDDS) and having the largest market share in the donepezil market, acquired approval for the Phase 3 clinical trial of donepezil patches from the Ministry of Food and Drug Safety.
According...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
